Akaso Sight-300 review: see in the dark (just not too far)

The Akaso Sight-300 is not a magic predator-vision helmet for (well) under $300. What it is is a genuinely interesting “see ...
RotoBaller on MSN

Week 8 Waiver Wire Pickups - Fantasy Football Free Agent Adds and Stashes (2025)

Rob's Week 8 fantasy football waiver wire pickups, adds, stashes and sleepers to target for 2025. His top waiver wire adds ...

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against ...

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...
PharmiWeb

Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled11-month open-label study will evaluate functional outcomes, safety, muscle composition ...

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...

NanoViricides Dual Track Clinical Strategy Explained by a Research Report – Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
The Malaysian Reserve

Ceragon Demonstrates E-Band Innovations in Tier-1 and ISP Deployments Across North America and Europe

E-band radios with auto-alignment and E-stabilizer innovations extend link distance and simplify 5G backhaul ROSH HA'AIN, Israel, Oct. 22, 2025 ...

United Homes Group Announces Conclusion of Review of Strategic Alternatives and Resignation of Directors

United Homes Group, Inc. (the “Company”) (NASDAQ: UHG), today announced that the special committee of independent directors (the “Special Committee”) previously appointed by the Board of Directors ...

Kairos Pharma, Ltd: Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopha ...

TIME CEO Jessica Sibley to Headline Health In Tech (HIT) Summit at Davos 2026: “AI and the Transformation of Legacy Systems”

TIME CEO Jessica Sibley to Headline HIT Summit Davos 2026 Panel on AI and the Transformation of Legacy Systems STUART, FL / ...
Le Lézard

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...